Top Markets
#1 Siren Siren +40.14%
#2 RedStone RedStone +24.77%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.65%
#4 Perle Perle +16.73%
#5 Ocean Protocol Ocean Protocol +15.17%
#6 KUB Coin KUB Coin +14.22%
#7 Verus Coin Verus Coin +13.72%
#8 Cysic Cysic +10.99%
#9 Quack AI Quack AI +10.58%
#10 Arowana Arowana +10.51%
Coin of the day
Siren Siren
設定
言語
日本
通貨
USD
テーマ
Ainos, Inc. Ainos, Inc.

Ainos, Inc.

AIMD
株式のランク #32150
Ainos, Inc. operates as a healthcare technology company, specializing in... Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
株価
$1.49
最終同期: 2026-08-17
時価総額
$10.94M
変化（1日）
4.58%
変化（1年）
-55.67%
国
US
取引 Ainos, Inc. (AIMD)

カテゴリー

Healthcare
Ainos, Inc.（AIMD）の収益
Aug 2026 時点の収益 TTM: 0
Ainos, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Ainos, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR